兴齐眼药：SQ-22031滴眼液完成首例受试者入组

Core Viewpoint - The company has initiated the Phase II clinical trial for its SQ-22031 eye drops, aimed at treating neurotrophic keratitis (NK), with the first subject enrolled in the trial [1] Group 1: Product Development - SQ-22031 eye drops are designed to promote the growth and survival of sensory and sympathetic neurons, restoring damaged neuron function, which can lead to rapid healing of corneal damage and improvement in corneal sensation and tear production [1] - As of the announcement date, there are no approved competing products for SQ-22031 eye drops in the market according to the National Medical Products Administration [1] Group 2: Clinical Trial Progress - The company has completed the enrollment of the first subject in the randomized, double-blind, placebo-controlled Phase II clinical trial for SQ-22031 eye drops [1] - The initiation of the Phase II clinical trial is not expected to have a significant impact on the company's recent financial performance [1]